Browse DLL1

Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Apical cell membrane Single-pass type I membrane protein Cell junction, adherens junction Membrane raft Note=Distributed around adherens junction in the apical endfeet through interactions with MAGI1.
Domain PF01414 Delta serrate ligand
PF00008 EGF-like domain
PF12661 Human growth factor-like EGF
PF07657 N terminus of Notch ligand
Function

Transmembrane ligand protein of NOTCH1, NOTCH2 and NOTCH3 receptors that binds the extracellular domain (ECD) of Notch receptor in a cis and trans fashion manner (PubMed:11006133). Following transinteraction, ligand cells produce mechanical force that depends of a clathrin-mediated endocytosis, requiring ligand ubiquitination, EPN1 interaction, and actin polymerisation; these events promote Notch receptor extracellular domain (NECD) transendocytosis and triggers Notch signaling through induction of cleavage, hyperphosphorylation, and nuclear accumulation of the intracellular domain of Notch receptors (NICD) (By similarity). Is required for embryonic development and maintenance of adult stem cells in many different tissues and immune systeme; the DLL1-induced Notch signaling is mediated through an intercellular communication that regulates cell lineage, cell specification, cell patterning and morphogenesis through effects on differentiation and proliferation (PubMed:11581320). Plays a role in brain development at different level, namely by regulating neuronal differentiation of neural precursor cells via cell-cell interaction, most likely through the lateral inhibitory system in an endogenous level dependent-manner. During neocortex development, Dll1-Notch signaling transmission is mediated by dynamic interactions between intermediate neurogenic progenitors and radial glia; the cell-cell interactions are mediated via dynamic and transient elongation processes, likely to reactivate/maintain Notch activity in neighboring progenitors, and coordinate progenitor cell division and differentiation across radial and zonal boundaries. During cerebellar development, regulates Bergmann glial monolayer formation and its morphological maturation through a Notch signaling pathway. At the retina and spinal cord level, regulates neurogenesis by preventing the premature differentiation of neural progenitors and also by maintaining progenitors in spinal cord through Notch signaling pathway. Also controls neurogenesis of the neural tube in a progenitor domain-specific fashion along the dorsoventral axis. Maintains quiescence of neural stem cells and plays a role as a fate determinant that segregates asymmetrically to one daughter cell during neural stem cells mitosis, resulting in neuronal differentiation in Dll1-inheriting cell. Plays a role in immune systeme development, namely the development of all T-cells and marginal zone (MZ) B-cells (By similarity). Blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with the characteristics of a T-cell/NK-cell precursor (PubMed:11581320). Also plays a role during muscle development. During early development, inhibits myoblasts differentiation from the medial dermomyotomal lip and later regulates progenitor cell differentiation. Directly modulates cell adhesion and basal lamina formation in satellite cells through Notch signaling. Maintains myogenic progenitors pool by suppressing differentiation through down-regulation of MYOD1 and is required for satellite cell homing and PAX7 expression. During craniofacial and trunk myogenesis suppresses differentiation of cranial mesoderm-derived and somite-derived muscle via MYOD1 regulation but in cranial mesoderm-derived progenitors, is neither required for satellite cell homing nor for PAX7 expression. Also plays a role during pancreatic cell development. During type B pancreatic cell development, may be involved in the initiation of proximodistal patterning in the early pancreatic epithelium. Stimulates multipotent pancreatic progenitor cells proliferation and pancreatic growth by maintaining HES1 expression and PTF1A protein levels. During fetal stages of development, is required to maintain arterial identity and the responsiveness of arterial endothelial cells for VEGFA through regulation of KDR activation and NRP1 expression. Controls sprouting angiogenesis and subsequent vertical branch formation througth regulation on tip cell differentiation. Negatively regulates goblet cell differentiation in intestine and controls secretory fat commitment through lateral inhibition in small intestine. Plays a role during inner ear development; negatively regulates auditory hair cell differentiation. Plays a role during nephron development through Notch signaling pathway. Regulates growth, blood pressure and energy homeostasis (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001708 cell fate specification
GO:0001709 cell fate determination
GO:0001756 somitogenesis
GO:0001757 somite specification
GO:0001818 negative regulation of cytokine production
GO:0001822 kidney development
GO:0001947 heart looping
GO:0002040 sprouting angiogenesis
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002067 glandular epithelial cell differentiation
GO:0002068 glandular epithelial cell development
GO:0002085 inhibition of neuroepithelial cell differentiation
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002313 mature B cell differentiation involved in immune response
GO:0002315 marginal zone B cell differentiation
GO:0002335 mature B cell differentiation
GO:0002366 leukocyte activation involved in immune response
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003013 circulatory system process
GO:0003143 embryonic heart tube morphogenesis
GO:0003158 endothelium development
GO:0003309 type B pancreatic cell differentiation
GO:0003323 type B pancreatic cell development
GO:0006898 receptor-mediated endocytosis
GO:0007219 Notch signaling pathway
GO:0007220 Notch receptor processing
GO:0007368 determination of left/right symmetry
GO:0007379 segment specification
GO:0007386 compartment pattern specification
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0008544 epidermis development
GO:0008593 regulation of Notch signaling pathway
GO:0009798 axis specification
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0009880 embryonic pattern specification
GO:0009913 epidermal cell differentiation
GO:0009952 anterior/posterior pattern specification
GO:0009954 proximal/distal pattern formation
GO:0010001 glial cell differentiation
GO:0010721 negative regulation of cell development
GO:0014002 astrocyte development
GO:0014706 striated muscle tissue development
GO:0014807 regulation of somitogenesis
GO:0016202 regulation of striated muscle tissue development
GO:0019827 stem cell population maintenance
GO:0021510 spinal cord development
GO:0021549 cerebellum development
GO:0021575 hindbrain morphogenesis
GO:0021587 cerebellum morphogenesis
GO:0021679 cerebellar molecular layer development
GO:0021680 cerebellar Purkinje cell layer development
GO:0021687 cerebellar molecular layer morphogenesis
GO:0021688 cerebellar molecular layer formation
GO:0021692 cerebellar Purkinje cell layer morphogenesis
GO:0021693 cerebellar Purkinje cell layer structural organization
GO:0021695 cerebellar cortex development
GO:0021696 cerebellar cortex morphogenesis
GO:0021697 cerebellar cortex formation
GO:0021698 cerebellar cortex structural organization
GO:0021782 glial cell development
GO:0022037 metencephalon development
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030100 regulation of endocytosis
GO:0030183 B cell differentiation
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030902 hindbrain development
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0032613 interleukin-10 production
GO:0032653 regulation of interleukin-10 production
GO:0032693 negative regulation of interleukin-10 production
GO:0032844 regulation of homeostatic process
GO:0034349 glial cell apoptotic process
GO:0034350 regulation of glial cell apoptotic process
GO:0034351 negative regulation of glial cell apoptotic process
GO:0035050 embryonic heart tube development
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0035270 endocrine system development
GO:0035282 segmentation
GO:0035315 hair cell differentiation
GO:0035883 enteroendocrine cell differentiation
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0040034 regulation of development, heterochronic
GO:0042063 gliogenesis
GO:0042113 B cell activation
GO:0042490 mechanoreceptor differentiation
GO:0042491 auditory receptor cell differentiation
GO:0042692 muscle cell differentiation
GO:0043010 camera-type eye development
GO:0043583 ear development
GO:0043588 skin development
GO:0045165 cell fate commitment
GO:0045168 cell-cell signaling involved in cell fate commitment
GO:0045445 myoblast differentiation
GO:0045446 endothelial cell differentiation
GO:0045604 regulation of epidermal cell differentiation
GO:0045605 negative regulation of epidermal cell differentiation
GO:0045607 regulation of auditory receptor cell differentiation
GO:0045608 negative regulation of auditory receptor cell differentiation
GO:0045631 regulation of mechanoreceptor differentiation
GO:0045632 negative regulation of mechanoreceptor differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045682 regulation of epidermis development
GO:0045683 negative regulation of epidermis development
GO:0045747 positive regulation of Notch signaling pathway
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045807 positive regulation of endocytosis
GO:0045844 positive regulation of striated muscle tissue development
GO:0045927 positive regulation of growth
GO:0045995 regulation of embryonic development
GO:0046331 lateral inhibition
GO:0048505 regulation of timing of cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048532 anatomical structure arrangement
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048630 skeletal muscle tissue growth
GO:0048631 regulation of skeletal muscle tissue growth
GO:0048633 positive regulation of skeletal muscle tissue growth
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048641 regulation of skeletal muscle tissue development
GO:0048643 positive regulation of skeletal muscle tissue development
GO:0048663 neuron fate commitment
GO:0048665 neuron fate specification
GO:0048708 astrocyte differentiation
GO:0048839 inner ear development
GO:0048871 multicellular organismal homeostasis
GO:0050768 negative regulation of neurogenesis
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051302 regulation of cell division
GO:0051961 negative regulation of nervous system development
GO:0060041 retina development in camera-type eye
GO:0060042 retina morphogenesis in camera-type eye
GO:0060113 inner ear receptor cell differentiation
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060562 epithelial tube morphogenesis
GO:0060563 neuroepithelial cell differentiation
GO:0060627 regulation of vesicle-mediated transport
GO:0060837 blood vessel endothelial cell differentiation
GO:0060839 endothelial cell fate commitment
GO:0060842 arterial endothelial cell differentiation
GO:0060844 arterial endothelial cell fate commitment
GO:0060846 blood vessel endothelial cell fate commitment
GO:0060847 endothelial cell fate specification
GO:0060853 Notch signaling pathway involved in arterial endothelial cell fate commitment
GO:0060972 left/right pattern formation
GO:0061053 somite development
GO:0061326 renal tubule development
GO:0061371 determination of heart left/right asymmetry
GO:0070986 left/right axis specification
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072014 proximal tubule development
GO:0072070 loop of Henle development
GO:0072073 kidney epithelium development
GO:0072080 nephron tubule development
GO:0072148 epithelial cell fate commitment
GO:0072583 clathrin-dependent endocytosis
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090596 sensory organ morphogenesis
GO:0097009 energy homeostasis
GO:0097101 blood vessel endothelial cell fate specification
GO:0097102 endothelial tip cell fate specification
GO:0097150 neuronal stem cell population maintenance
GO:0098727 maintenance of cell number
GO:0098773 skin epidermis development
GO:1900746 regulation of vascular endothelial growth factor signaling pathway
GO:1901342 regulation of vasculature development
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1902547 regulation of cellular response to vascular endothelial growth factor stimulus
GO:1903670 regulation of sprouting angiogenesis
GO:1903672 positive regulation of sprouting angiogenesis
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1904018 positive regulation of vasculature development
GO:2000505 regulation of energy homeostasis
GO:2000980 regulation of inner ear receptor cell differentiation
GO:2000981 negative regulation of inner ear receptor cell differentiation
Molecular Function GO:0005112 Notch binding
GO:0008134 transcription factor binding
GO:0030957 Tat protein binding
GO:0097110 scaffold protein binding
Cellular Component GO:0016324 apical plasma membrane
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04330 Notch signaling pathway
Reactome R-HSA-2122948: Activated NOTCH1 Transmits Signal to the Nucleus
R-HSA-2691232: Constitutive Signaling by NOTCH1 HD Domain Mutants
R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2660826: Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-2979096: NOTCH2 Activation and Transmission of Signal to the Nucleus
R-HSA-156988: Receptor-ligand binding initiates the second proteolytic cleavage of Notch receptor
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2691230: Signaling by NOTCH1 HD Domain Mutants in Cancer
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-2660825: Signaling by NOTCH1 t(7;9)(NOTCH1
R-HSA-1980145: Signaling by NOTCH2
R-HSA-1980148: Signaling by NOTCH3
R-HSA-1980150: Signaling by NOTCH4
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DLL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DLL1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26404003Lung CacinomaPromote immunity (infiltration, T cell function)Systemic DLL-1 administration increased T-cell infiltration into tumors and elevated numbers of CD44(+)CD62L(+)CD8(+) memory T cells while decreasing the number of regulatory T cells and limiting tumor vascularization. This treatment was associated with upregulation of Notch and its ligands in tumor-infiltrating T cells enhanced expression of T-bet and phosphorylation of Stat1/2.
21825014Lung CarcinomaPromote immunityHere, we report a novel mechanism of escape from T-cell immunity that is caused by reduction in levels of the Delta family Notch ligands DLL1 and DLL4 in hematopoietic microenvironments. An important mediator of this effect was an elevation in the levels of circulating VEGF. Selective activation of the DLL1-Notch signaling pathway in bone marrow precursors enhanced T-cell activation and inhibited tumor growth.
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DLL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DLL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4270.219
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7270.315
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2080.727
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0630.838
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0820.963
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2410.908
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4890.242
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3730.0619
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.490.545
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4810.491
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9930.276
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4030.00371
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DLL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DLL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DLL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DLL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DLL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DLL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DLL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDLL1
Namedelta-like 1 (Drosophila)
Aliases delta (Drosophila)-like 1; DL1; H-Delta-1; drosophila Delta homolog 1; Delta-like protein 1
Chromosomal Location6q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DLL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.